◎ Sugi Atlas

Atlas / Disease / Cholelithiasis

Cholelithiasis

disease
On this page

Also known as gallstones

Summary

Cholelithiasis (MONDO:0012672) is a disease with 3 cohort genes (233 GWAS associations across 60 studies) and 141 clinical trials. Top therapeutic interventions include ursodiol, ondansetron, and acetaminophen.

At a glance

  • Cohort genes: 3
  • GWAS associations: 233
  • Clinical trials: 141

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namecholelithiasis
Mondo IDMONDO:0012672
EFOEFO:0004799
MeSHD002769
DOIDDOID:10211
ICD-10-CMK80
ICD-111268183934
NCITC122822
SNOMED CT266474003
UMLSC0008350
MedGen3039
Is cancer (heuristic)no

Also known as: gallstones

Data availability: 233 GWAS associations (60 studies).

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › biliary tract disorder › cholelithiasis

Related subtypes (14): bile duct disorder, biliary tract neoplasm, gallstones, primary biliary cholangitis, bile reflux, postcholecystectomy syndrome, Alagille syndrome, isolated agenesis of gallbladder, ketamine-induced biliary dilatation, follicular cholangitis and pancreatitis, idiopathic ductopenia, Caroli syndrome, isolated congenital hepatic fibrosis, Rokitansky-Aschoff sinuses of the gallbladder

Subtypes (4): cholecystolithiasis, choledocholithiasis, gallbladder disease 1, primary intrahepatic lithiasis

Genetics & variants

GWAS landscape

233 GWAS associations across 60 studies. Top hits map to 25 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs562664641e-300ABCG5?1.95
rs118875341e-176ABCG8C0.75
rs42993763e-116ABCG8?0.77
rs46815159e-53TM4SF4G0.13
rs728009502e-51LRPPRC - PPM1B-DT?1.69
chr2:440697723e-46G0.25
rs41483256e-41UGT1A10, UGT1A4, UGT1A6, UGT1A5, UGT1A7, UGT1A1, UGT1A3, UGT1A8, UGT1A9C0.13
rs784513567e-41DYNC2LI1?0.82
rs20816876e-39UBXN2B - CYP7A1C0.12
rs18009612e-38HNF4AT0.32
chr3:1494937256e-38A0.1
rs67201733e-37ABCG5?1.19
chr19:478716935e-37A0.14
rs22908461e-36LRBAA0.12
rs41488052e-36ABCB4A0.14
chr8:584647987e-36A0.11
chr7:875010811e-32T0.14
rs621299665e-32SULT2A1A0.16
chr4:1502779286e-31A0.1
rs29548051e-29ABCG8?1.14
rs104262012e-28SULT2A1?0.85
chr20:444137242e-28T0.24
chr10:454857364e-28C0.1
rs622720212e-27TM4SF4A0.43
rs172098371e-26ABCB4 - ABCB1?0.85
rs8878295e-25UGT1A6, UGT1A7, UGT1A8, UGT1A5, UGT1A10, UGT1A9, UGT1A4, UGT1A3A0.19
rs112395497e-25MARCHF8G0.11
rs26382805e-24FUT2 - MAMSTR?0.9
chr12:1209846455e-24T0.08
rs9838121e-23UBXN2B - CYP7A1?1.12

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90432140Jiang Y2023116,382213,325A cross-disorder study to identify causal relationships, shared genetic variants, and genes across 21 digestive disorders.
GCST90473879UK Biobank Whole-Genome Sequencing Consortium202533,249425,191Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90018819Sakaue S202126,122461,431A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90476100Verma A202423,182416,631Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476101Verma A202418,237421,370Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90080297Backman JD202117,665367,776Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084283Backman JD202117,665367,776Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90297596Auwerx C202417,496305,627Rare copy-number variants as modulators of common disease susceptibility.
GCST90297650Auwerx C202417,496305,627Rare copy-number variants as modulators of common disease susceptibility.
GCST90297702Auwerx C202417,496305,627Rare copy-number variants as modulators of common disease susceptibility.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding6
Tier 2: splice/UTR2
Tier 3: regulatory0
Tier 4: intronic/intergenic42

MAF distribution

BucketVariants
common (>=0.05)33
low_freq (0.01-0.05)1
rare (<0.01)0
unknown16

Functional consequences

ConsequenceCount
intron_variant18
unknown15
intergenic_variant9
missense_variant6
3_prime_UTR_variant2

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs75331444243842633G>A0.05intron_variantABCG8Tier 4: intronic/intergenic
chr2:43839108Tier 4: intronic/intergenic
rs56266464243827852G>A,C0.05intron_variantABCG51e-300Tier 4: intronic/intergenic
rs11887534243839108G>A,C0.066missense_variantABCG81e-176Tier 1: coding
rs4299376243845437G>C,T0.05intron_variantABCG83e-116Tier 4: intronic/intergenic
rs46815153149494289A>G0.05intron_variantTM4SF49e-53Tier 4: intronic/intergenic
rs72800950244112677T>Aintergenic_variantLRPPRC - PPM1B-DT2e-51Tier 4: intronic/intergenic
chr2:440697720.0673e-46Tier 4: intronic/intergenic
rs41483252233764663C>T0.324intron_variantUGT1A10, UGT1A4, UGT1A6, UGT1A5, UGT1A7, UGT1A1, UGT1A3, UGT1A8, UGT1A96e-41Tier 4: intronic/intergenic
rs78451356243806615T>A,G0.05intron_variantDYNC2LI17e-41Tier 4: intronic/intergenic
rs2081687858476006T>A,C,G0.05intergenic_variantUBXN2B - CYP7A16e-39Tier 4: intronic/intergenic
rs18009612044413724C>T0.05missense_variantHNF4A2e-38Tier 1: coding
chr3:1494937256e-38Tier 4: intronic/intergenic
rs6720173243813262G>C0.05missense_variantABCG53e-37Tier 1: coding
chr19:478716935e-37Tier 4: intronic/intergenic
rs22908464150277928G>A0.05missense_variantLRBA1e-36Tier 1: coding
rs4148805787477049G>A,T0.05intergenic_variantABCB42e-36Tier 4: intronic/intergenic
chr8:584647987e-36Tier 4: intronic/intergenic
chr7:875010811e-32Tier 4: intronic/intergenic
rs621299661947871693C>A,T0.05intron_variantSULT2A15e-32Tier 4: intronic/intergenic
chr4:1502779286e-31Tier 4: intronic/intergenic
rs2954805243882019G>A,C0.053_prime_UTR_variantABCG81e-29Tier 2: splice/UTR
rs104262011947881492G>A,T0.05intron_variantSULT2A12e-28Tier 4: intronic/intergenic
chr20:444137242e-28Tier 4: intronic/intergenic
chr10:454857364e-28Tier 4: intronic/intergenic
rs622720213149487795G>A0.044intron_variantTM4SF42e-27Tier 4: intronic/intergenic
rs17209837787495506T>C0.05intergenic_variantABCB4 - ABCB11e-26Tier 4: intronic/intergenic
rs8878292233759924C>A,G,T0.45intron_variantUGT1A6, UGT1A7, UGT1A8, UGT1A5, UGT1A10, UGT1A9, UGT1A4, UGT1A35e-25Tier 4: intronic/intergenic
rs112395491045523383A>G0.05intron_variantMARCHF87e-25Tier 4: intronic/intergenic
rs26382801948706061G>A0.05intergenic_variantFUT2 - MAMSTR5e-24Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 5 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
UGT1A1Orphanet:2312Transient familial neonatal hyperbilirubinemia
UGT1A1Orphanet:79234Crigler-Najjar syndrome type 1
UGT1A1Orphanet:79235Crigler-Najjar syndrome type 2
ABCG8Orphanet:2882Sitosterolemia
ABCG8Orphanet:391665Homozygous familial hypercholesterolemia

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only3

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
UGT1A1HGNC:12530ENSG00000241635P22309UDP-glucuronosyltransferase 1A1gwas
UGT1A10HGNC:12531ENSG00000242515Q9HAW8UDP-glucuronosyltransferase 1A10gwas
ABCG8HGNC:13887ENSG00000143921Q9H221ATP-binding cassette sub-family G member 8gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
UGT1A1UDP-glucuronosyltransferase 1A1UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into eit…
UGT1A10UDP-glucuronosyltransferase 1A10UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into eit…
ABCG8ATP-binding cassette sub-family G member 8ABCG5 and ABCG8 form an obligate heterodimer that mediates Mg(2+)- and ATP-dependent sterol transport across the cell membrane.

Protein-family classification

Druggable: 3 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Transporter125.9×0.038
Enzyme (other)28.0×0.038

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
UGT1A1Enzyme (other)yes2.4.1.17UDP_glucos_trans, UDP_glycos_trans_CS, UDP-glycosyltransferase
UGT1A10Enzyme (other)yes2.4.1.17UDP_glucos_trans, UDP_glycos_trans_CS, UDP-glycosyltransferase
ABCG8TransporteryesABC_transporter-like_ATP-bd, ABC2_TM, ABC_transporter-like_CS

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)3
unknown0

Top tissues across cohort

TissueCohort genes
duodenum2
liver2
right lobe of liver2
mucosa of transverse colon1
rectum1
jejunal mucosa1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
UGT1A179tissue_specificmarkerduodenum, right lobe of liver, liver
UGT1A1060tissue_specificmarkermucosa of transverse colon, duodenum, rectum
ABCG866tissue_specificmarkerright lobe of liver, liver, jejunal mucosa

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

SymbolInteractor count
ABCG81,920
UGT1A11,446
UGT1A101,373

Intra-cohort edges

ABSources
UGT1A1UGT1A10intact

Structural data

PDB: 1 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
ABCG8Q9H2218

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
UGT1A10Q9HAW892.11
UGT1A1P2230991.19

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 17. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Glucuronidation2507.6×8e-05UGT1A1, UGT1A10
Paracetamol ADME2282.0×1e-04UGT1A1, UGT1A10
Defective UGT1A1 causes hyperbilirubinemia13806.7×0.001UGT1A1
Defective ABCG8 causes GBD4 and sitosterolemia11903.3×0.002ABCG8
Defective ABCG5 causes sitosterolemia11903.3×0.002ABCG8
Heme degradation1271.9×0.010UGT1A1
ABC transporters in lipid homeostasis1200.3×0.012ABCG8
ABC transporter disorders1146.4×0.014ABCG8
NR1H2 and NR1H3-mediated signaling1131.3×0.014ABCG8
Aspirin ADME1105.7×0.015UGT1A1
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux1102.9×0.015ABCG8
Disorders of transmembrane transporters146.4×0.030ABCG8
ABC-family protein mediated transport140.5×0.032ABCG8
Signaling by Nuclear Receptors134.0×0.035ABCG8
Transport of small molecules18.4×0.130ABCG8
Disease14.4×0.226ABCG8
Signal Transduction13.4×0.267ABCG8

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
flavone metabolic process211234.7×0e+00UGT1A1, UGT1A10
glucuronate metabolic process25617.3×4e-07UGT1A1, UGT1A10
negative regulation of fatty acid metabolic process22808.7×2e-06UGT1A1, UGT1A10
liver development2147.8×6e-04UGT1A1, UGT1A10
bilirubin conjugation15617.3×1e-03UGT1A1
toxin catabolic process15617.3×1e-03UGT1A10
xenobiotic metabolic process299.4×1e-03UGT1A1, UGT1A10
negative regulation of intestinal phytosterol absorption12808.7×0.001ABCG8
pigment accumulation12808.7×0.001UGT1A1
negative regulation of intestinal cholesterol absorption12808.7×0.001ABCG8
negative regulation of steroid metabolic process12808.7×0.001UGT1A1
hepatic stellate cell activation11872.4×0.002UGT1A1
sterol transport1936.2×0.003ABCG8
connective tissue replacement1802.5×0.003UGT1A1
flavonoid metabolic process1702.2×0.004UGT1A1
heme catabolic process1510.7×0.005UGT1A1
intestinal cholesterol absorption1468.1×0.005ABCG8
response to arsenic-containing substance1401.2×0.005UGT1A1
protein heterooligomerization1351.1×0.006UGT1A1
retinoic acid metabolic process1267.5×0.007UGT1A1
phospholipid transport1234.1×0.008ABCG8
estrogen metabolic process1208.1×0.009UGT1A1
response to muscle activity1193.7×0.009ABCG8
xenobiotic catabolic process1187.2×0.009UGT1A10
cholesterol efflux1175.5×0.009ABCG8
digestive tract development1175.5×0.009UGT1A1
triglyceride homeostasis1160.5×0.009ABCG8
canonical NF-kappaB signal transduction1122.1×0.011UGT1A1
steroid metabolic process1112.3×0.012UGT1A1
response to nutrient198.5×0.013ABCG8

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
UrsodiolPhase 3 (in late-stage trials)

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 1

Druggability breadth: 2 of 3 evidence-associated genes (67%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
UGT1A1ATAZANAVIR
UGT1A10DICLOFENAC

Top cohort targets by molecule count

SymbolMoleculesMax phase
UGT1A1124
UGT1A1024
ABCG800

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
ATAZANAVIR4UGT1A1
DICLOFENAC4UGT1A1, UGT1A10
KETOCONAZOLE4UGT1A1
LEVOTHYROXINE4UGT1A1
RITONAVIR4UGT1A1
ETHINYL ESTRADIOL4UGT1A1
CARVEDILOL4UGT1A1
HYMECROMONE2UGT1A1
FIPRAVIRIMAT2UGT1A1
NIFLUMIC ACID2UGT1A1
DAIDZEIN2UGT1A1
BAICALEIN2UGT1A1
EPIESTRIOL2UGT1A10

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
UGT1A1174ADMET:159, Binding:15
UGT1A10101ADMET:99, Binding:2

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
UGT1A12.4.1.17glucuronosyltransferase
UGT1A102.4.1.17glucuronosyltransferase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
UGT1A1174
UGT1A10101

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 1.

Cohort genes with a CPIC/DPWG dosing guideline

SymbolCPIC guidelines
UGT1A11

Chemical tractability of cohort targets

13 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
ATAZANAVIR4UGT1A1
DICLOFENAC4UGT1A1, UGT1A10
KETOCONAZOLE4UGT1A1
LEVOTHYROXINE4UGT1A1
RITONAVIR4UGT1A1
ETHINYL ESTRADIOL4UGT1A1
CARVEDILOL4UGT1A1
HYMECROMONE2UGT1A1
FIPRAVIRIMAT2UGT1A1
NIFLUMIC ACID2UGT1A1
DAIDZEIN2UGT1A1
BAICALEIN2UGT1A1
EPIESTRIOL2UGT1A10

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)2UGT1A1, UGT1A10
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug1ABCG8
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
ABCG80—

Clinical trials & evidence

Clinical trials

Clinical trials: 141.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified113
PHASE414
PHASE25
PHASE34
PHASE13
PHASE1/PHASE22

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00042549PHASE4TERMINATEDLithotripsy for the Treatment of Gallstones
NCT00674713PHASE4COMPLETEDEffect of Acupuncture on Postoperative Nausea and Vomiting
NCT00836316PHASE4COMPLETEDLevobupivacaine During Cholecystectomy
NCT01052727PHASE4UNKNOWNDay-care Versus Overnight-stay Laparoscopic Cholecystectomy Randomized Controlled Trial.
NCT01104727PHASE4COMPLETEDMulti-Port Versus Single-port Cholecystectomy
NCT01339325PHASE4UNKNOWNLaparo-endoscopic Single Site (LESS) Cholecystectomy Versus Standard LAP-CHOLE
NCT01397565PHASE4COMPLETEDMinilaparoscopic Versus Conventional Laparoscopic Cholecystectomy
NCT01822262PHASE4UNKNOWNContrastive Study for Minimally Invasive Cholecystolithotomy With Gallbladder Reservation and Laparoscopic Cholecystectomy
NCT01888822PHASE4TERMINATEDAntibiotic Prophylaxis in Laparoscopic Cholecystectomy
NCT02056678PHASE4WITHDRAWNOutcome of IV Acetaminophen Use in Laparoscopic Cholecystectomies in Patients at Risk of OSA
NCT02363699PHASE4COMPLETEDEndovenous Lidocaine and Serum Cytokines Concentration
NCT02472509PHASE4TERMINATEDThe Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders
NCT03168555PHASE4COMPLETEDChanges in Bile Acid Homeostasis and Stool Habits After Cholecystectomy
NCT03180229PHASE4COMPLETEDGranisetron Effect on Hemodynamic Changes in Laparoscopic Cholecystectomy
NCT00835250PHASE3COMPLETEDLaparoscopic Cholecystectomy vs Hybrid Natural Orifice Translumenal Surgery
NCT01099319PHASE3COMPLETEDRenalof in the Treatment of Elderly Patients With Gallstones
NCT01558414PHASE3COMPLETEDSingle Incision Laparoscopic Surgery vs Flexible Single Incision Surgery for Cholecystectomy
NCT02721862PHASE3UNKNOWNEffectiveness of Ursodeoxycholic Acid Use in the Prevention of Gallstone Formation After Sleeve Gastrectomy
NCT07012772PHASE2RECRUITINGCOMBO Endoscopy Oropharyngeal Airway in Sedated Endoscopic Retrograde Cholangiopancreatography for Patients
NCT07051980PHASE2RECRUITINGFeasibility and Safety of Supraglottic Oxygen Delivery Via an Endotracheal Tube for Non-intubated ERCP Anesthesia: A Two-Stage Phase II Clinical Study
NCT00710502PHASE1/PHASE2COMPLETEDTransvaginal NOTES Cholecystectomy: Phase I/II Mexico Clinical Trial
NCT00910325PHASE1/PHASE2TERMINATEDNatural Orifice Translumenal Endoscopic Surgery: Laparoscopic-Assisted Transvaginal Cholecystectomy
NCT01625026PHASE2COMPLETEDObeticholic Acid in Bariatric and Gallstone Disease
NCT02325492PHASE2TERMINATEDMedical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study
NCT02947256PHASE2COMPLETEDLaparoscopic Cholecystectomy With Retro-infundibular Approach
NCT00240123PHASE1WITHDRAWNEffect of Benadryl Sedation During ERCP or EUS
NCT00678873PHASE1COMPLETEDSingle Incision Laparoscopic Cholecystectomy
NCT00815438PHASE1WITHDRAWNTransvaginal Cholecystectomy Using Endoscopic Assistance
NCT05210322Not specifiedACTIVE_NOT_RECRUITINGPercutaneous Cholangiopancreatoscopy Registry
NCT06113419Not specifiedRECRUITINGTiming of CHolecystectomy In Severe PAncreatitis
NCT06123117Not specifiedRECRUITINGSTALL vs Sole Local Wound Infiltration in Laparoscopic Cholecystectomy
NCT06468774Not specifiedRECRUITINGIntestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia
NCT06852937Not specifiedRECRUITINGUsing da Vinci SP System for Patients With Cholelithiasis and Choledocholithiasis
NCT06873594Not specifiedNOT_YET_RECRUITINGComparison of Three Ports and Four Ports Laparoscopic Cholecystectomy
NCT06926374Not specifiedRECRUITINGProspective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
NCT07001423Not specifiedRECRUITINGChOlecystectomy aFter successFul Endoscopic Common Bile Duct Stone Extraction in Elderly
NCT07119203Not specifiedRECRUITINGSurgical Techniques: Robotic Versus Conventional Laparoscopic Cholecystectomy IN Benign Gallbladder Disease
NCT07245108Not specifiedRECRUITINGThe Pro-Chol Study
NCT07308730Not specifiedRECRUITINGPain Diary Use After Laparoscopic Cholecystectomy
NCT07452848Not specifiedRECRUITINGImpact of Pringle Maneuver on Postoperative Gallbladder Diseases After Hepatectomy

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
URSODIOL46
ONDANSETRON43
ACETAMINOPHEN41
CHENODIOL41
CIPROFLOXACIN41
GRANISETRON41
KETAMINE HYDROCHLORIDE41
LEVOBUPIVACAINE41
OBETICHOLIC ACID41
ICOMIDOCHOLIC ACID31
CHEMBL540958302
CHEMBL39953801
CHEMBL430368001
CHEMBL519724401
CHEMBL541270101

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 73

This page pulls from 73 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncicd10cmicd11intactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot